Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Safety profile of oseltamivir during the 2009 influenza pandemic.
Pharmacoepidemiol Drug Saf. 2011 May;20(5):532-43. doi: 10.1002/pds.2136.
Pharmacoepidemiol Drug Saf. 2011.
PMID: 21448900
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.
Kwon JM, Arya K, Kuntz N, Phan HC, Sieburg C, Swoboda KJ, Veerapandiyan A, Assman B, Bader-Weder S, Dickendesher TL, Hansen J, Lin H, Yan Y, Rao VK; US Expanded Access Program Working Group.
Kwon JM, et al. Among authors: bader weder s.
Ann Clin Transl Neurol. 2022 Jun;9(6):810-818. doi: 10.1002/acn3.51560. Epub 2022 May 14.
Ann Clin Transl Neurol. 2022.
PMID: 35567422
Free PMC article.
Item in Clipboard
MedDRA Labeling Groupings to Improve Safety Communication in Product Labels.
Große-Michaelis I, Proestel S, Rao RM, Dillman BS, Bader-Weder S, Macdonald L, Gregory W.
Große-Michaelis I, et al. Among authors: bader weder s.
Ther Innov Regul Sci. 2023 Jan;57(1):1-6. doi: 10.1007/s43441-022-00393-1. Epub 2022 Aug 8.
Ther Innov Regul Sci. 2023.
PMID: 35939205
Free PMC article.
Item in Clipboard
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Mercuri E, Baranello G, Boespflug-Tanguy O, De Waele L, Goemans N, Kirschner J, Masson R, Mazzone ES, Pechmann A, Pera MC, Vuillerot C, Bader-Weder S, Gerber M, Gorni K, Hoffart J, Kletzl H, Martin C, McIver T, Scalco RS, Yeung WY, Servais L; SUNFISH Working Group.
Mercuri E, et al. Among authors: bader weder s.
Eur J Neurol. 2023 Jul;30(7):1945-1956. doi: 10.1111/ene.15499. Epub 2022 Aug 1.
Eur J Neurol. 2023.
PMID: 35837793
Clinical Trial.
Item in Clipboard
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.
Trottier B, et al. Among authors: bader weder s.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c.
J Acquir Immune Defic Syndr. 2005.
PMID: 16280695
Clinical Trial.
Item in Clipboard
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arastéh K, Chung J, Rowell L, Guimaraes D, Bertasso A; TORO 1 and TORO 2 Study Groups.
Cooper DA, et al.
HIV Med. 2011 Jan;12(1):31-9. doi: 10.1111/j.1468-1293.2010.00845.x.
HIV Med. 2011.
PMID: 20497250
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite